Treatment and endpoints. – AIEOP-BFM ALL – AIEOP-BFM ALL • Perspectives. ALL, acute lymphoblastic leukemia; MRD, minimal residual disease. Principal investigator of clinical trial. Pr Martin SCHRAPPE; Klinik für Kinder- und Jugendmedizin I; Universitätsklinikum Schleswig-Holstein – Campus Kiel. Blood ; doi: .. Accordingly, in the AIEOP-BFM ALL study, these 2 groups of patients.
|Published (Last):||11 October 2007|
|PDF File Size:||10.38 Mb|
|ePub File Size:||18.63 Mb|
|Price:||Free* [*Free Regsitration Required]|
In the case of non-availability of at least two sensitive MRD markers sensitivity at least 10 -4MRD risk group stratification can also be based on only one sensitive marker. Giles1 Anita Y.
Our results suggested that use of MRD criteria based on a single timepoint day 15 or day 33 would not be helpful but that stratification could be improved by using both early timepoints. Date study was aoeop-bfm in EudraCT. Author information Article notes Copyright and License information Disclaimer. Clonal rearrangements of immunoglobulin and T-cell receptor genes had previously been identified for each patient by PCR and sequencing.
Is it possible to improve the outcome and to achieve a further reduction of leukemic cell burden by administration of an innovative treatment schedule DNX-FLA? Identification of a new poor early response group within medium risk for MRD risk stratification. Cancer AND drug name. The al, analysis of precursor B and T-ALL patients in BFM protocols has improved our understanding of response to therapy and risk .
Conceived and designed the experiments: Table 1 Characteristics of the patient cohort for this study.
Summary Details Full Trial Details. Trials shown on current page Selected Trials only.
Clinical Trials Register
This study was funded by project grants and from the National Health and Medical Research Council www. Pediatr Blood Cancer New agents with proven benefit in the frontline therapy of ALL have not been identified, therefore, chemotherapy could only be improved by more effective combination of existing agents.
Clinical trials for AIEOP-BFM ALL 2009
Parental consent was given for all aiop-bfm at the hospitals and a copy forwarded to CCIA. Reviewed and contributed to the manuscript and approved final form: The morphological examination of bone marrow aspirates at day 15 was established early as a prognostic indicator of poor outcome  and this remains relevant in BFM trials particularly when MRD measurement is not feasible .
The potential benefit of this alternative patient stratification is clear from a comparison of the original stratification Figure 5B and the new alternative Figure 5C. Query did not match any studies. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
ROC analysis is used to assess the diagnostic accuracy of a continuous variable and to estimate the threshold which optimizes the balance between sensitivity true positive rate and specificity true negative rate . Marshall13 Murray D. These thresholds, rounded to the nearest half log value, were applied in survival analyses. Obtained funding MN MH. The value of MRD at even earlier aaieop-bfm in induction day 15 or day 19 in the identification of patients with particularly favourable 200 has already been established for MRD measured by quantitative flow cytometry  and in small PCR-MRD studies  qieop-bfm .
These data collectively suggested that the early MRD timepoints can provide additional prognostic information useful for stratifying patients with precursor B-ALL.
Trial documentation Melanie Gerzmehle Univ.